RAF expression in human astrocytic tumors

CARSTEN HAGEMANN1, JENS GLOGER1, JELENA ANACKER2, HARUN M. SAID3, STEFANIE GERNGRAS1, SIGLINDE KÜHNEL1, CHRISTOPH MEYER4, ULF RÜDIGER RAPP5, ULRIKE KÄMMERER2, DIRK VORDERMARK3, MICHAEL FLENTJE3, KLAUS ROOSEN1 and GILES HAMILTON VINCE1

1Department of Neurosurgery, Tumorbiology Laboratory, University of Würzburg, Josef-Schneider-Str. 11; Departments of 2Obstetrics and Gynaecology, 3Radiation Oncology, University of Würzburg, Josef-Schneider-Str. 4, D-97080 Würzburg; 4Department of Medicine II, Molecular Alcohol Research in Gastroenterology, Faculty of Medicine at Mannheim, University of Heidelberg, Theodor-Kutzer-Ufer 1-3, D-68167 Mannheim; 5Institut für Medizinische Strahlenkunde und Zellforschung (MSZ), University of Würzburg, Versbacher Str. 5, D-97078 Würzburg, Germany

Received August 29, 2008; Accepted October 6, 2008

Abstract. RAF proteins are well known oncoproteins. The B-RAF has been shown to be activated by mutations in a multitude of human cancers. Alterations of C-RAF expression are discussed to play a role in lung cancer. Only for A-RAF no link to tumorigenesis has been published so far. Malignant gliomas are the most prevalent primary brain tumors of adults. They are highly invasive and very difficult to treat, despite of surgery, γ-irradiation and chemotherapy. Although a role of the mitogenic Ras-RAF-MEK-ERK signalling cascade in brain tumor development is well established, there are only few reports available addressing alterations in RAF sequence or protein expression and function in human gliomas. We analysed the mutational status of A-RAF and B-RAF in human glioblastomas (GBM) by sequencing. Then we checked for RAF gene amplification by dot blot hybridization and examined RAF mRNA and protein expression patterns in human astrocytic gliomas of WHO grade II (LGA) and IV (GBM) by semiquantitative RT-PCR and Western blotting, respectively. The results were correlated with patients prognosis. Finally, we performed functional assays to address a putative function of A-RAF in glioma cell proliferation and migration. We showed that RAF mutations are a rare event in glioblastoma multiforme. A-raf gene amplification was more often detected and overexpression of all three RAF proteins on mRNA and protein level was regularly found in human malignant gliomas. Whereas A-RAF and C-RAF expression was negatively correlated with the patients prognosis, B-RAF expression had a positive effect. Since neither A-RAF, nor C-RAF expression had any influence on proliferation and migration of GBM cells, putative functions of C-RAF in angiogenesis and of A-RAF in regulation of metabolism are discussed. Our data indicate that RAF proteins might be valuable targets for small molecule therapies. However, initially specific functions of RAF during tumorigenesis have to be elucidated.

Introduction

Diffuse astrocytomas WHO grade II (low grade astrocytomas, LGA) are well differentiated tumors with diffuse infiltration of the adjacent brain parenchyma (1). Despite their relatively slow growth, this infiltrating behavior is one reason for a median survival of patients in the range of only 5 years after diagnosis (2,3). In addition, most of these tumors progress to anaplastic astrocytomas WHO grade III or glioblastoma multiforme (GBM) within 4-5 years after diagnosis (4). GBM are the most prevalent, highly malignant, invasive and difficult to treat primary brain tumors of adults. This tumor can either develop by progression from less malignant gliomas or de novo without any precursor lesion (1). Treatment regimen of patients with GBM include neurosurgical tumor resection followed by local γ-irradiation and chemotherapy (1). However, in spite of such multi-disciplinary treatment the median survival is <14 months (5).

Nowadays, more targeted therapies based on small molecules are in development. These therapies aim to block signalling pathways, which are specifically altered during progression of astrocytic gliomas (6). Already in early stages there are gains of chromosome 7 or 7q in >50% of all LGA (7,8). About 60% of these tumors carry mutations in the p53 tumor suppressor gene, accompanied by loss of heterozygosity (LOH) on chromosome 17p (9,10). This results in complete absence of wild-type p53. Frequently, elevated expression of the platelet-derived growth factor receptor α (PDGFRα) and the corresponding ligand PDGFβ are observed, arguing for a growth stimulating autocrine loop (11,12). This leads to activation of mitogenic signalling pathways, such as the
mitogen-activated protein kinase (MAPK) cascade. In anaplastic astrocytoma WHO grade III mutations in cell cycle regulatory genes, like e.g., CDKN2A, CDKN2B, pRB1, CDK4, CDK6, CCND1 or CCND3, are seen in addition to the above-mentioned alterations (1). GBM additionally demonstrate deletion of chromosome 10 and alteration of the phosphoinositide 3-kinase (PI3K)/protein kinase B (Akt) signalling pathway (1). In about 60% of cases there is overexpression and in ~40% amplification of the epidermal growth factor receptor (EGFR) gene (6). Therefore, recent developments in small-molecule therapies aim to target these receptors and their downstream signalling pathways. Gefitinib (Iressa®; Astra Zeneca Pharmaceuticals, Wilmington, DE) and Erlotinib (Tarceva®; OSI Pharmaceuticals, Inc., Melville, NY) are two examples for targeted drugs directed against EGFR activity and Imatinib mesylate (Gleevec®; Norvartis Pharmaceuticals Corp.) has inhibitory effects on the PDGFR. All these drugs are currently in phase II studies (6).

These tyrosine kinase receptors have in common that they stimulate the mitogenic Ras-Raf-MEK-ERK signalling cascade. Human malignant astrocytomas frequently display the active GTP bound form of Ras, and thereby proliferation of these cells is increased (13). Co-expression of active Akt and oncogenic H-Ras in neuronal progenitor cells (14) and specific expression of oncogenic H-Ras under control of the glial fibrillary acidic protein (GFAP) promoter in astrocytes (15), respectively, causes GBM formation with the histological features of human GBM in mouse models. Ras proteins belong to the group of small G-proteins and convey receptor signalling to the cytoplasmic Raf protein serine/threonine kinases which then signal through MEK and ERK to regulate a wide range of cellular functions, including protein synthesis, transcription, angiogenesis, cell cycle, cell proliferation and cell survival (16-18). Three Raf proteins are known: A-Raf, B-Raf and C-Raf. Whereas there is no evidence yet that A-Raf may be involved in tumor progression (19-21), a role for mutated and activated B-Raf, especially B-Raf V600E (formerly described as B-Raf V599E) (22), in melanomas and in ovarian, thyroid and colorectal carcinomas is well established (21,23,24). A putative role for C-Raf in lung cancer development is discussed (18,25,26). Treatment is well established (21,23,24). A putative role for C-Raf in melanomas and in ovarian, thyroid and colorectal carcinomas (18,25,26).

Materials and methods

Tissue samples. Informed consent of the patient was obtained for the acquisition of tumor material as approved by the local ethics committee. All tissue samples were obtained from patients treated in the University Hospital Würzburg. The patients underwent surgical tumor resection followed by radiotherapy and Temozolomide chemotherapy. However, two glioblastoma multiforme WHO grade IV (GBM) samples (2369 and 2423) were from recurrent tumors pretreated with γ-irradiation and chemotherapy. Expression of Raf was analysed using three samples of temporal brain tissue (normal brain, NB), derived from patients with epilepsy (kindly provided by Thomas Freiman, University Hospital Freiburg im Breisgau, Germany), 15 low grade astrocytomas WHO grade II (LGA) and 15 GBM. Details about patient's sex, age, diagnosis, location of tumor and treatment regimen for these samples have been described previously (33).

Immediately after surgery tissue samples were frozen at -80°C and then stored in liquid nitrogen. The classification of human brain tumors used in this study was determined by routine histology based on criteria of the World Health Organisation (34).

Cells, cell culture and cell transfection. Human GBM cell lines U87, U251 and U373 were purchased from ATCC (American Type Culture Collection, Rockville, MD), and GaMG was established from a patient with glioblastoma multiforme (Gade Institut of the University Bergen, Norway) (35). Cells were grown under the conditions reported elsewhere (36) in 75 cm² flasks (Corning, New York, USA) at 37°C, 5.0% CO₂ and 100% humidity.

Cells were passaged two days prior to transfection by nucleofection (Amaza, Cologne, Germany) and grown to 80% confluency. Subsequently, cells were trypsinised (0.25% Trypsin-EDTA; Invitrogen, Heidelberg, Germany), washed with phosphate-buffered saline (PBS) and for each transfection 1x10⁶ cells were resuspended in 100 μl nucleofection solution V (Amaza). Of each plasmid 2 μg (pCMV5; pCMV5-A-Raf) was added and nucleofected using programme T-20 (36). The same conditions were used for siRNA transfection. The sequences of the control siRNA scrambled and the siRNA targeting A-Raf have already been published (36,37). They were synthesized by Qiagen (Hilden, Germany). In total, 3 μg siRNA were used per transfection. Transfected cells were transferred to 6-well plates and incubated for 24 h or more, as described. The generation of spheroids, which were used for migration assays, is described elsewhere (36).

Isolation of genomic DNA, RNA and protein. Genomic DNA was isolated from 10-20 mg tissue samples and 3 ml frozen blood samples, respectively, using the wizard genomic DNA purification kit (Promega, Heidelberg, Germany) according to the manufacturer's manual. Isolated DNA was dissolved in 100 μl (tissue) or 250 μl (blood) rehydration buffer and stored at -20°C.
Trypsinised cells were washed twice with PBS and then resuspended in 50 μl PBS. Total mRNA and protein was purified from these cells and from 30 mg of surgical specimens, respectively, by the Nucleo-Spin RNA/Protein Kit (Macherey-Nagel, Düren, Germany) according to the manufacturer’s instructions. During extraction RNA was treated with RNase-free DNase I to eliminate DNA contaminations in the samples, as recommended by the manufacturer. The RNA samples were eluted with 60 μl RNase-free water and proteins were solubilized in 100 μl protein loading buffer (PLB) containing 50 mM Tris (2-carboxyethyl) phosphine hydrochloride (TCEP) reducing agent. Purified RNA samples were stored at -80°C and protein/PLB-TCEP mixtures at -20°C.

For Western blot detection of proteins after transfection and protein knock-down in spheroids, spheroids not used for migration assays were sedimented and solubilized with 50 μl lysis buffer (10 mM Tris-Cl pH 7.4, 150 mM NaCl, 1 mM EDTA, 1 mM EGTA, 1% (v/v) Triton X-100, 0.5% (v/v) IGEPAL CA-630, 1 mM PMSF, 10 μg/ml leupeptin, 23 μg/ml aprotinin). Cells from monolayer cultures (proliferation assay) were solubilized in a concentration of 17,000 cells/μl lysis buffer. Of each lysate 32.5 μl was mixed with 5 μl NuPage Sample Reducing Agent and 12.5 μl LDS sample buffer (both from Invitrogen). All protein lysates were stored at -20°C.

DNA sequencing. A-raf exons 10 and 13 and B-raf exons 11 and 15 were amplified by polymerase chain reaction (PCR) from genomic DNA using primers and conditions shown in Table I. PCR products were sequenced using BigDye Terminator Cycle Sequencing Ready Reaction Kit (Applied Biosystems, Foster City, CA, USA) according to the manufacturer’s manual, and analyzed on an ABI PRISM 3100 Avant Genetic Analyzer. The sequences were first analyzed by visual inspection, looking for double peaks or untypical background signals. Additional alignments with the published genomic sequence were performed using the multiple sequence alignment software MAFFT version 6 (38) and box-shades for better visual analysis were generated online using BOXSHADE 3.21 (39).

Southern blotting. Probes directed against genomic DNA sequences of the three raf-genes were generated by PCR using primers shown in Table I. The PCR was performed using 2.5 U Taq polymerase in each 25 μl reaction, containing 10X buffer with 1.5 mM MgCl₂ (Eppendorf, Hamburg, Germany). Thermocycle parameters were as follows: 5 min at 94°C; 37 cycles of 30 sec at 94°C, 30 sec at the respective annealing temperature (Table I), 30 sec at 72°C; and 10 min at 72°C. PCR products were dissolved in 15 μl H₂O and denatured for 10 min at 95°C. After cooling down on ice, DIG-dNTP labelling was performed by adding 2 μl hexanucleotide mixture (Roche Applied Science, Mannheim, Germany), 2 μl DIG-dNTPs (Roche Applied Science) and 10 U Klenow fragment (MBI Fermentas, Burlington, Canada). After 60-min incubation at 37°C the reaction was stopped by adding 2 μl of a 0.2 M EDTA solution pH 8.0. The DNA-probes were precipitated by adding 2.5 μl of a 3 M Na-acetate solution pH 4.5 and 75 μl ethanol. After 30-min incubation at -70°C DNA was sedimented by 30-min
centrifugation at 13,000 x g, 4°C. The pellet was washed once with 70% ethanol, dried in a speed-vac and dissolved in 50 μl TE buffer (10 mM Tris, 1 mM EDTA, pH 8.0).

Genomic DNA was isolated as described above and 10 μg of each sample was applied to a positively charged nylon membrane (Schleicher & Schüll, Dassel, Germany) for dot hybridization. The dots were dried and crosslinked under UV radiation descending from 120,000 to 0 μJ. Hybridization was performed according to the manual of the DIG Luminescent Detection Kit (Roche Applied Science), except that incubation took place in 100 ml antibody solution, equilibration in 100 ml detection buffer and development in 50 ml of a 1:100 dilution of CSPD in detection buffer.

**Western blotting.** Expression of RAF proteins was determined by Western blotting. In total, 3-10 μl of the protein/PLB-TCEP mixture, 25 μl of spheroid lysates and 20 μl of monolayer lysates per lane were separated on NuPage® 3-8% Tris-acetate polyacrylamide gels (Invitrogen) and transferred to nitrocellulose membranes (Schleicher & Schüll). After blocking in 5% milk powder, the membranes were incubated with rabbit polyclonal anti-RAF antibodies (Raf-A, Raf-B, Raf-1; Santa Cruz, CA, USA) or sheep anti-mouse IgG (Amersham Pharmacia Biotech). Secondary antibodies: goat anti-rabbit IgG HRP (Santa Cruz, CA, USA) or sheep anti-mouse IgG HRP (Amersham Pharmacia Biotech, Braunschweig, Germany), both diluted 1:1000 in TBST. Blots were incubated with horseradish peroxidase (HRP) conjugated secondary antibodies: goat anti-rabbit IgG HRP (Santa Cruz, CA, USA) or sheep anti-mouse IgG HRP (Amersham Pharmacia Biotech) and visualized using the ECL-immunodetection system (Amersham Pharmacia Biotech). The intensity of the DNA and protein bands was quantified by densitometry using the BioDocAnalyze software (Biometra, Göttingen, Germany) or sheep anti-mouse IgG HRP (Amersham Pharmacia Biotech, Braunschweig, Germany), both diluted 1:1000 in TBST. After washing in TBST, the membrane was incubated with rabbit polyclonal anti-ß-actin (Abcam, Cambridge, UK) antibody was diluted 1:1000, mouse monoclonal anti-γ-tubulin primary antibody (Sigma) was used at a dilution of 1:5000 and mouse monoclonal anti-ß-actin antibody (Sigma) was diluted 1:10000 in TBST. After washing in TBST, the membrane was washed with 0.07 μg/ml ethidium bromide (Roth, Karlsruhe, Germany) containing 0.1% (v/v) Tween-20.

**Semiquantitative RT-PCR analysis.** Expression of RAF mRNA was analysed by semiquantitative RT-PCR following a standard protocol (33,40). The amount of cDNA was normalized to the amount of the housekeeping gene ß-actin. cDNA amplification and expression analysis was performed using primers given in Table I. These primers were designed in flanking exons with Primer3 software (41). PCR conditions were as described above for Southern blot probe generation, except that cycles given in Table I were used. These PCR conditions were optimized for each primer-pair. The amplification products were separated on 1% agarose gels (Sigma, Deisenhofen, Germany) containing 0.07 μg/ml ethidium bromide (Roth, Karlsruhe, Germany).

**Migration assay.** Spheroids of equal size (200 μm in diameter) were transferred to 96-well plates 48 h after transfection. The wells were coated with 0.01% poly-D-lysine (Sigma) and single tumor spheroids were placed in the middle of each well. The area covered by the spheroid and by cells spreading out from the spheroid was documented 0, 12, 24, 36 and 46 h after placing the spheroids. This migration area was morphometrically assessed in percent of the original spheroid radius using a stereomicroscope and a non-commercial specialized software (42). The experiment was performed with a minimum number of 5 spheroids per transfection (Table IV).

**Proliferation assay.** Cells were transfected as described above. Cells (2x10⁶) were seeded on 60 mm Petri-dishes (Corning, New York, USA) after transfection and given 24 h to recover from the transfection procedure. After that, cells were trypsinised and 5x10⁴ cells were seeded in 60 mm Petri-dishes, filled with 3 ml medium, each. Cells were then harvested at 24-h intervals over a period of 7 days by trypsinisation and counted using a Fuchs-Rosenthal chamber. The fold increase in cell number compared to day 3 after transfection was calculated to establish growth curves. Experiments were run in triplicate.

**Statistical analysis.** The intensity of the DNA and protein bands was quantified by densitometry using the BioDocAnalyze software (Biometra, Göttingen, Germany) and the DNA and protein bands were normalized with respect to ß-actin and γ-tubulin, respectively. Statistical analysis was performed using Microsoft Office Excel 2003 (Microsoft Deutschland GmbH, Unterschleissheim, Germany). Values were expressed as means ± standard error of the mean. Statistical significance was defined by two tailed t-tests and p<0.05 was considered to be significant. Box-Plots were generated using GraphPad Prism 4 Software (GraphPad Software Inc., San Diego, USA) and statistical significance was determined by analysis of variance (ANOVA).

**Results**

Activating mutations of RAF proteins are rare in human astrocytic tumors. B-RAF was found activated by mutations in a multitude of human cancers with highest incidence in malignant melanoma (21,23,24). These hot-spot mutations concentrate in exons 11 and 15 of B-raf (23,24). For A-RAF a comparable sequence analysis is only available for ovarian epithelial tumors, gastric adenocarcinomas, acute leukemias and colorectal carcinomas, without any mutations detected (20,43). Therefore, we amplified the coding sequences of A-raf exon 10 and A-raf exon 13 from 66 and 63 GBM samples, respectively, by PCR and subjected them to sequence analysis (Table II). These exons correspond to the above-mentioned B-raf exons. However, no nucleotide exchange which would alter the amino acid sequence of the A-RAF protein was detected. In one case, a single nucleotide polymorphism was...
found in A-raf exon 10, where the cytosine at position 1001 was replaced by a thymidine (Fig. 1a). The absence of a double peak at this position indicates that it is a homozygous polymorphism. In addition, this was not a tumor specific alteration, because the same exchange was detected in peripheral blood leukocytes of the patient (Fig. 1a).

B-raf exon 11 and B-raf exon 15 were also analysed in 74 and 44 GBM biopsies, respectively (Table II). No nucleotide exchange was detected in B-raf exon 11. However, the tumor of one patient harboured the hot-spot mutation T1799A leading to the activating amino acid exchange V600E (Fig. 1b). This GBM-patient was progression-free for 5 years after initial surgery and chemotherapy, before recurrent disease appeared. In this recurrent GBM tissue the same B-RAF T1799A mutation was found (Fig. 1b). The double peak in the sequence at this position indicates that the mutation was heterozygous (Fig. 1b). In addition, this sequence alteration was tumor specific, since analysis of a peripheral blood sample from the patient revealed a wild-type B-raf sequence (Fig. 1b).

A-RAF but not B-RAF or C-RAF shows allelic gains in human astrocytic tumors. The fact that activating RAF mutations only occur in about 2% of the analysed GBM does not necessarily mean that RAF proteins are not involved in brain tumor development. Therefore, we checked for amplification of the different raf genes by dot blot hybridization. Equal amounts of genomic DNA from 15 low grade astrocytoma (WHO grade II, LGA) and 15 GBM were dotted onto a membrane and hybridized with RAF isoform specific probes. Patient gender was evenly distributed in the two groups of LGA and GBM (33). We got strong signals suggesting amplification of the A-raf gene in at least one of the LGA (tumor 2201) and one of the GBM (tumor 2414) (Fig. 2).

RAF mRNA expression is increased in human astrocytic tumors in comparison to normal tissue. To confirm overexpression of A-RAF by these tumors, we analysed mRNA expression of the three RAF isoforms in the above-mentioned panel of 15 LGA and 15 GBM by semiquantitative RT-PCR (Fig. 3). In addition, three normal brain tissues (NB) were screened. Compared to these NB samples, tumors 2201 and 2414 showed increased expression of A-RAF mRNA, whereas they did not display a major change in the expression strength of B-RAF or C-RAF mRNA (Fig. 3). Generally, expression of the three RAF family members was detectable in nearly all samples analysed. Only A-RAF was not demonstrable in some LGA and GBM samples (Figs. 3a and 6a). Whereas B-RAF and C-RAF showed a nearly homogeneous distribution, A-RAF displayed a high diversity in expression strength between the different glioma samples (Fig. 3a). Densitometric quantification was performed on a scale from 0 to 100 (zero meaning no expression detectable, 100 representing the strongest RAF expression within the panel: C-RAF expression of tumor 2329). Each value was normalized to the corresponding expression of the housekeeping gene β-actin and results were presented in form of box-plots. This analysis revealed that there was a successive increase of A-RAF mRNA expression from NB via LGA to GBM (Fig. 3b). The fluctuation range of B-RAF and C-RAF mRNA expression was increased in tumor tissue compared to NB (Fig. 3c and d). Although there was no difference between the maximum and minimum relative expression values of B-RAF mRNA in LGA compared to GBM, the mRNA expression of C-RAF was increased in all types of tumors compared to NB (Fig. 3d).

**Table II. RAF-sequence alterations in glioblastoma multiforme (GBM).**

<table>
<thead>
<tr>
<th>GBM samples analysed</th>
<th>Mutation</th>
<th>No. of samples with mutations</th>
</tr>
</thead>
<tbody>
<tr>
<td>A-RAF exon 10</td>
<td>C1001T→A334A</td>
<td>1</td>
</tr>
<tr>
<td>A-RAF exon 13</td>
<td>-</td>
<td>0</td>
</tr>
<tr>
<td>B-RAF exon 11</td>
<td>-</td>
<td>0</td>
</tr>
<tr>
<td>B-RAF exon 15</td>
<td>T1799A→V600E</td>
<td>1</td>
</tr>
</tbody>
</table>

**Table III. Median survival time (weeks) of patients with strong and weak expression of RAF mRNA and protein.**

<table>
<thead>
<tr>
<th>mRNA</th>
<th>A-RAF</th>
<th>B-RAF</th>
<th>C-RAF</th>
<th>Protein</th>
<th>A-RAF</th>
<th>B-RAF</th>
<th>C-RAF</th>
</tr>
</thead>
<tbody>
<tr>
<td>mRNA</td>
<td></td>
<td></td>
<td></td>
<td>Protein</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>21.6</td>
<td>86.4</td>
<td>97.3</td>
<td>24.9</td>
<td>32.9</td>
<td>100.1</td>
<td>18.7</td>
</tr>
<tr>
<td>Weak expression</td>
<td>64.7</td>
<td>19.6</td>
<td>n.a.</td>
<td>29.4</td>
<td>29.3</td>
<td>19.6</td>
<td>29.4</td>
</tr>
<tr>
<td>Difference</td>
<td>-43.1</td>
<td>+66.8</td>
<td></td>
<td>-4.5</td>
<td>+3.6</td>
<td>+80.5</td>
<td>-10.7</td>
</tr>
</tbody>
</table>

*Strong vs. no expression, n.a., not applicable.
median relative expression of B-RAF mRNA was reduced from 60.3 and 57.5 in NB and LGA, respectively, to 44.9 in GBM (Fig. 3c). In contrast, C-RAF mRNA expression was increased in GBM compared to LGA (Fig. 3d).

These alterations in RAF mRNA expression were reflected by the number of tumors in the sample set showing no, weak (>0 but <50 on the above described scale) or strong (≥50) RAF mRNA signals (Fig. 6a). B-RAF and C-RAF were expressed by all samples analysed (Fig. 6a). Whereas there was no change in the percentage of tumors with strong C-RAF expression (100% NB, 93% LGA, 100% GBM), strong B-RAF expression was reduced from 67% of NB and 67%
of LGA to 33% of the GBM (Fig. 6a). A-RAF mRNA expression showed highest fluctuations. All NB samples had weak A-RAF expression, but in 7% of LGA and 20% of GBM there was no A-RAF mRNA detectable. In addition, 7% of GBM displayed strong A-RAF mRNA expression (Fig. 6a). Our analysis did not reveal any significant influence of gender, treatment regimen, recurrent vs. primary tumor or the location of the tumor on RAF expression levels.

Concentrations of RAF-proteins are regularly increased in human astrocytic tumors. Since the mRNA expression does not necessarily have to be correlated with protein expression (33,40), we were anxious to confirm our RT-PCR data by Western blotting. Therefore, we optimized the antibodies using total cell-lysates of human glioblastoma cell lines U87, U251, U343, U373 and GaMG (Fig. 4). In all these cell lines the three RAF isoforms were detectable (Fig. 4a), however they were expressed in different concentrations (Fig. 4b). Whereas U87 displayed weakest A-RAF expression, followed by U251, the other cell lines tested expressed this RAF protein nearly equally (Fig. 4). It is known that there are several B-RAF splice variants detectable (44-46). We checked for

Figure 2. Southern dot blot analysis of raf genomic DNA content in 15 LGA and 15 GBM. Genomic DNA was isolated from tumor biopsies and 10 μg DNA of each sample dot blotted onto a positively charged nylon membrane. RAF-isoform specific probes were DIG-dNTP labelled and luminescence was detected. Boxes indicate tumor samples with amplified A-raf gene compared to B-raf and C-raf.

Figure 3. Expression analysis of RAF mRNA in NB and human astrocytic tumor samples by semiquantitative RT-PCR. (a) Total RNA from normal brain (NB), astrocytoma WHO grade II (LGA) and glioblastoma multiforme (GBM) tissue samples was used as template for RT-PCR analysis. Primers, specific for each transcript, were designed in flanking exons. cDNA from U251 cells was used as positive control (+). For negative control cDNA was excluded from the PCR reaction (−). The various cDNA concentrations were normalized to that of the housekeeping gene β-actin, which was used as internal loading control. The size (bp) of the A-RAF, B-RAF- C-RAF and β-actin cDNA fragment is indicated on the right. The numbers refer to the tumor samples used (33). (b) Box-plot analysis of densitometrically quantified A-RAF mRNA expression. Each value was normalized to the respective β-actin mRNA. The black line within the boxes represents the median expression, boxes show the quartiles and bars indicate minimum and maximum values. (c) Box-plot analysis of densitometrically quantified B-RAF mRNA expression. (d) Box-plot analysis of densitometrically quantified C-RAF mRNA expression.
expression of the 95 and the 68 kDa splice variant of B-RAF in the glioblastoma cell-lines. Both forms were strongly expressed by U87 cells and weakly by U251 cells (Fig. 4a). In U343, U373 and GaMG, however, clear expression only of the 95 kDa splice variant was detectable, whereas there was no expression of the 68 kDa form (Fig. 4a). Therefore, the 68 kDa form was excluded from the densitometric analysis and only the expression strength of 95 kDa B-RAF is shown in Fig. 4b. C-RAF was strongly expressed by U87 and U251 cells, but weakly by U343, U373 and GaMG (Fig. 4).

These results encouraged us to perform Western blot analysis with total protein lysates of the same tumor samples used for the RT-PCR screening to detect RAF protein expression in the tissue. We found a clear increase of both, overall protein expression and number of tumor samples expressing A-RAF, 95 kDa B-RAF and C-RAF concomitant with increasing WHO grading of the tumor (Figs. 5 and 6b). The high diversity of RAF expression between different tumors, already observed on mRNA level, was even more profound on protein level (Figs. 5 and 6b). Interestingly, A-RAF was detectable as a double band of equal strength in the tumor samples (Fig. 5a). It was only very weakly expressed by NB (Fig. 5a and b). Several LGA and GBM showed A-RAF expression with a clear increase in expression strength in GBM (Fig. 5a and b and Fig. 6b). Whereas the 95-kDa splice variant of B-RAF was clearly detectable in NB, increased in its expression strength in LGA and was even more elevated in GBM (Figs. 5c and 6b), the 68-kDa
B-RAF form was absent in NB, then strongly appeared in LGA and was slightly reduced in its average relative expression in GBM (Fig. 5a and c and Fig. 6b). C-RAF was overexpressed by glioma tissue compared to NB (Fig. 5a and d), but not much altered in GBM when compared to LGA. However, variation of average relative expression was increased in GBM (Fig. 5a and d).

Expression of RAF-proteins in paraffin-embedded GBM sections. Western blotting shows that the three RAF isoforms A-RAF, B-RAF and C-RAF are expressed by human astrocytic tumor samples. However, they do not reveal which cell-types within the tumor section display expression. Therefore, we performed immunohistochemistry using paraffin-embedded tissue sections derived from a number of different GBMs. Tissue stained with appropriate isotype control antibodies served as negative control (Fig. 7d). Immunostaining clearly confirmed the expression of the three RAF isoforms in tumor tissue (Fig. 7). A-RAF was expressed throughout the tumor tissue. The cytoplasm of nearly every tumor cell was stained (Fig. 7a). B-RAF showed a very similar expression throughout the tumor section in the cytoplasm of individual, large tumor cells (Fig. 7b). C-RAF staining, in contrast, showed highest concentrations in the endothelial cells around blood vessels, but there were also some tumor cells strongly stained and some blood vessels without signal (Fig. 7c).

Influence of RAF expression on patient’s prognosis. Western blot analysis showed a high diversity of RAF expression between different tumors (Fig. 5a). Therefore, we were interested, whether RAF expression is correlated with the patient’s median survival (Table III). Strong expression of A-RAF mRNA correlated with a reduction in the median survival by 43.1 weeks. However, A-RAF protein expression had only a marginal effect (Table III). In contrast, B-RAF mRNA expression and the expression of the 68-kDa splice variant of the B-RAF protein correlated with increased median survival by 66.8 and 80.5 weeks, respectively (Table III). The 95-kDa form of B-RAF had only a marginal, but also positive effect. C-RAF protein expression in turn was negatively correlated with the patient’s prognosis, since the median survival was reduced by 10.7 weeks (Table III). It was not possible to perform survival studies for C-RAF mRNA expression, because it was strongly expressed by nearly all patients (Fig. 3a).

A-RAF overexpression or knock-down does not influence tumor cell migration and proliferation. Since increase of A-RAF expression on mRNA and protein level was seen concomitantly with increasing WHO grading of the glioma (Figs. 3 and 5) and since A-RAF mRNA expression was negatively correlated with patients survival (Table III), we were interested to investigate, whether A-RAF expression does influence the migration behavior or proliferation rate of GBM cells. We transfected U251 cells with pCMV5 empty vector, pCMV5-A-RAF for transient A-RAF overexpression, scrambled siRNA and siRNA for a specific A-RAF knock-down (Fig. 8a). Spheroids for a migration assay were generated from these cells and the distance of cells spreading out from the spheroid was documented 0, 12, 24, 36 and 46 h after placing the spheroid (Fig. 8b and Table IV). In addition, 50,000 of the transfected cells were seeded onto 60 mm plates for a proliferation assay and increase of cell number was counted over a period of seven days (Fig. 8c and Table V). Western blotting of these proliferating cells showed transient A-RAF overexpression at day two, which then quickly diminished to normal level starting at day three (Fig. 8d). siRNA mediated A-RAF knock-down lasted for more then 4 days and started to diminish at day 6 (Fig. 8d). In both, the migration and the proliferation assay, there was no statistically significant difference between cells expressing normal, increased or decreased concentrations of A-RAF protein.

Discussion

Human primary glioblastomas are characterized by amplification (>40% of cases) or overexpression (>60% of cases)
Figure 7. RAF expression on paraffin-embedded sections of a representative glioblastoma sample. (a-c) RAF expression (brown signal) was visualized by staining with specific antibodies. (a) A-RAF expression was detected in the cytoplasm of nearly all tumor cells throughout the section. (b) Expression of B-RAF by several large tumor cells throughout the section. (c) C-RAF was specifically found in the cytoplasm of endothelial cells around blood vessels but also in several tumor cells. (d) Tissue stained with appropriate isotype control antibodies served as negative control. All slides were magnified x40.

Figure 8. Effect of transient overexpression and siRNA knock-down of A-RAF in cultured U251 glioblastoma cells on their migration behavior and proliferation rate. (a) Western blot analysis of A-RAF overexpression and knock-down. Cells have been transfected with 2 μg pCMV5 empty vector as control, 2 μg plasmid pCMV5-A-RAF for A-RAF overexpression, 3 μg control siRNA scrambled and 3 μg A-RAF specific siRNA, respectively. ß-tubulin served as loading control to ensure that equal protein concentrations have been loaded onto the gel. Shown is the effect 72 h after transfection. (b) Migration of U251 cells. Spheroids of this cell-line have been planted onto poly-L-lysine coated plates. The distance between cells migrating away from the spheroid and the border of the original spheroid has been measured at the indicated time-points. Error-bars have been excluded from the figure for clarity reasons. However, the standard errors of the mean (SE) are given in Table IV. (c) Proliferation of U251 cells. 50,000 transfected cells have been plated at day 0 onto 60-mm plates. Over a period of seven days cells have been trypsinized and counted each day. Error-bars have been excluded from the figure for clarity reasons. However, the standard errors of the mean (SE) are given in Table V. (d) After counting, cells have been lysed and analysed for A-RAF overexpression and knock-down, respectively, by Western blotting.
of the epidermal growth factor receptor (EGFR) gene (6). The most common mutation associated with EGFR amplification is a large in-frame deletion of the cellular domain (EGFRvIII), which turns this receptor constitutively active (47,48). Such EGFR overexpression and activation is positively correlated with GBM malignancy (6).

The classical signalling cascade activated by EGFR is the mitogenic Ras-RAF-MEK-ERK pathway, which is involved in regulation of a wide range of cellular functions (16-18). Receptor activation leads to activation of Ras protein family members, a group of small G-proteins (49). It has been shown that ~30% of human tumors contain activating mutations in one of the three Ras genes, K-ras and N-ras and H-ras (24,50). Although the majority of GBM display elevated levels of Ras-GTP (13), and although overexpression of H-Ras can induce GBM formation in mouse models (14,15), activating mutations in ras genes are very rare or absent in malignant gliomas (29,32,51).

Therefore, we concentrated in our analysis on members of the protein serine/threonine kinase family activated by Ras proteins, A-RAF, B-RAF and C-RAF, a family of well-known oncproteins. However, data on their role in development of human astrocytic gliomas are limited.

We analysed the mutational status of A-RAF and B-RAF in human GBM. Then we checked for RAF gene amplification by dot blot hybridization and analysed RAF mRNA and protein expression in three NB, 15 LGA and 15 GBM biopsies. The results from the expression analysis were correlated with patients’ prognosis. Finally, we performed functional assays to address a putative function of A-RAF in glioma cell proliferation and migration.

Malignant alterations in exons 11 and 15 of B-RAF have been found in melanomas and in ovarian, thyroid and colorectal carcinomas (23). Most prominent was the T1799A (B-RAF V600E) exchange, accounting for 80% of the mutations found (23). Although this exchange also was detected in 11% (4 of 38) glioma cell lines, no mutations were found in 15 primary gliomas (23). However, in our screen of 44 GBM biopsies we detected one case with a heterozygous, tumor specific T1799A mutation, leading to the activating amino acid exchange V600E (Fig. 1b). No mutations were found in exon 11 of 74 analysed GBM samples (Table II). Therefore, 2% of GBM patients contained oncogenically activated B-RAF proteins in their tumors. This percentage is in accordance with findings of other groups. One study describes two T1799A mutations among 94 GBM (2%) (29) and another reports two of the same alterations in 34 GBM (6%) (30). This means that in total ~3% (5 of 187) of all GBM contain activating B-RAF mutations, a small percentage in comparison to other malignancies.

A-RAF has not been analysed for mutations in GBM, yet. Therefore, we screened 66 GBM samples for mutations in exons corresponding to the mutationaly most affected B-raf exons (Table II). We did not find any sequence alterations, except for one silent polymorphism in exon 10 of A-raf, leading to a C1001T exchange (Fig. 1a). The same genetic variant has been described in one case in a screen of 130 primary colorectal tumors for oncogenic B-RAF mutations (43). In this screen and in another, addressing A-raf sequence alterations in ovarian epithelial tumors, colorectal carcinomas, gastric adenocarcinomas and acute leukemias, no A-raf mutations were detected (20).

For C-RAF no mutations have been found either (43). The reason may be that both proteins may require multiple mutations for oncogenic activation, whereas B-RAF can be activated by a single base change, like e.g., T1799A (21). In addition, even certain tumor-associated inactivating B-RAF mutations have been shown to activate the mitogenic signalling pathway by heterodimerization of B-RAF with wild-type C-RAF (52-54), indicating that more than just one RAF family member may be necessary for oncogenic transformation. However, although the mitogenic signalling cascade plays a pivotal role during development of human gliomas, mutations of raf genes are a rare event in GBM. Therefore,
we checked for other alterations leading to changes in RAF expression.

Dot blot hybridization suggested amplification of the A-raf gene in at least one out of 15 LGA and one out of 15 GBM (Fig. 2).Astrocytic tumors display a high level of aneuploidy already in early stages (55-57). It is discussed that aneuploidy leads to an imbalance of the signalling network in tumor cells with loss of tumour-suppressor genes and overexpression of oncogenes (57-59). The A-raf gene is located on Xp11.2 (16), a chromosome often numerically altered in human gliomas. Recently, it has been shown that a high percentage of gliomas also shows gains in B-raf gene copy number and that such changes may lead to higher B-RAF expression and signalling (32). In our dot blot assay we did not find such alterations. However, our methodology can detect chromosomal amplification, but is not sensitive enough to reveal gene copy gains. Conventional comparative genomic hybridization (CGH) arrays would be necessary. B-raf is encoded at 7p34 (16). Gain of this chromosome is the most common chromosomal abnormality in LGA, found in >50% of cases and leads to the observed EGFR amplification (1). B-raf gene copy gains have also been observed in follicular thyroid adenoma and follicular thyroid carcinoma (60). The development of lung adenocarcinomas and retro-aortic lymphomas in mouse models is accompanied by very high expression of normal sized C-RAF mRNA and protein, compared to normal cells (61). Together, these findings suggest that overexpression of RAF proteins may participate in the tumorigenic process. Indeed, we saw increased levels of A-RAF mRNA and protein expression in the two tumors with A-RAF amplification, whereas they did not display a major change in the expression strength of B-RAF or C-RAF.

Semiquantitative RT-PCR analysis of 15 LGA, 15 GBM and three normal brain (NB) samples revealed B-RAF and C-RAF mRNA expression homogeneously in nearly all samples analysed (Fig. 3a). Only A-RAF was not demonstrable in some LGA and GBM samples and displayed a high diversity in expression strength between the different glioma samples. Densitometric analysis confirmed the diverse expression and showed a successive increase of A-RAF mRNA expression from NB via LGA to GBM (Fig. 3b). Recently, we showed that our methodology is sufficient to detect alterations in mRNA expression if astrocytic tumors of different WHO grade are compared with each other (33,62).

More important than mRNA expression is the presence of functional protein in the tumor cell. Already in 1989 expression of C-RAF has been analysed in 18 different GBM cell lines by Northern blot hybridization. All cell lines tested expressed mRNA of this protein (63). Here, we confirmed these data by Western blotting of total lysates from U87, U251, U343, U373 and GaMG cells and also included analysis of A-RAF and B-RAF expression (Fig. 4). We found that all tested cell lines expressed the three RAF isoforms, but that expression strength differed between the different cell lines (Fig. 4b). This is in correspondence with findings of others who in addition screened THR, D54MG, T98G, D645MG, D423 and D566MG GBM cell lines positively for RAF protein expression (28).

Looking at our tumor biopsy panel by Western blotting, the individually diverse RAF expression was even more profound on protein level than on mRNA level and also the differences between NB, LGA and GBM were more impressive (Fig. 5). A-RAF was only very weakly expressed by NB and increased noticeably via LGA to GBM. Interestingly, A-RAF was detectable as a doublet of equal strength in the tumor samples (Fig. 5a). Although two splice variants, resulting in truncated A-RAF proteins of 21 kDa (DA-RAF1) and 17 kDa (DA-RAF2), are known (64), our double bands were too large (68 kDa) to correspond with them. In addition, the antibodies used for detection were directed against C-terminal epitopes not present in the splice variants. Therefore, we do not have data concerning expression of DA-RAF in astrocytic tumors. Yureyev et al also observed an A-RAF double band when they analysed A-RAF localization in mitochondria of cells from rat liver by Western blotting (65). They were not able to resolve the nature of distinction between the double bands and suggested posttranslational protein modification by phosphorylation or proteolytic peptide removal (65). Such alterations of A-RAF protein also may occur in brain tumor cells.

More then 10 different splice variants are known for B-RAF in a range from 67 to 99 kDa (45,46). In neuronal tissues like spinal cord and brain the longer splice variants predominate (45). Here, we checked for expression of 95 and 68 kDa B-RAF in our panel of human gliomas. Whereas 68 kDa B-RAF was absent in NB, then strongly appeared in LGA and was slightly reduced again in its average expression in GBM, the 95 kDa band was clearly detectable in all samples analysed (Fig. 5). It showed a gradual increase in expression concomitantly with increasing WHO grading, as did C-RAF protein expression (Fig. 5).

Generally, we detected an increase of protein expression with rising WHO grade of the tumor for all three RAF isoforms. The impact of this RAF expression became obvious when we correlated it with patients survival. Although the sampling was too small for statistically significant results, tendencies are clear. Whereas expression of A-RAF and C-RAF mRNA and protein had a negative effect on patients survival, B-RAF expression was positively correlated with prognosis (Table III). Expression of the 68-kDa splice variant of B-RAF extended the median survival by 80.5 weeks and the patient with a tumor-specific activating B-RAF V600E amino acid exchange (Fig. 1) survived with stable disease for 5 years, before he relapsed. In colorectal carcinomas and malignant melanomas similar observations have been made. All patients harbouring activating B-RAF mutations in their colon carcinomas survived without recurrence compared to only 75% of 5 year survival in B-RAF negative cancers (66), and melanoma patients with B-RAF mutations exhibited a median survival of 12 months compared to 5 months median survival of patients without B-RAF mutations (22). However, other authors neither observed a positive, nor a negative influence of activated B-RAF in malignant melanomas, but reported a negative effect in metastasis (67). The positive effect of B-RAF expression may be due to its high activity (21,68). It has been shown that strong and sustained B-RAF signals will induce cell cycle arrest, differentiation and senescence of cells (24,54,69-72). In addition, B-RAF V600E expression leads to synthesis and secretion of IGFBP7, which inhibits in an autocrine/paracrine loop the B-RAF-MEK-ERK...
signalling and thereby induces senescence and apoptosis (73).

Our analysis revealed that A-RAF and C-RAF expression exerts a negative effect on patient's prognosis (Table III). High grade human gliomas are characterized by increased proliferation and migration activities of the tumor cells. Therefore, the effect of transient RAF overexpression and RNAi mediated gene knock-down in GBM cell lines has been investigated for A-RAF by us (Fig. 8) and for C-RAF by others (31). None of these experiments was associated with any change, neither of proliferation rates, nor of migration behavior (Fig. 8) (31). However, siRNA mediated knock-down of C-RAF in human cerebral microvascular endothelial cells (HCMEC) led to a reduction of cell survival and significant inhibition of tube formation and therefore might be involved in neoangiogenesis (31). This view is supported by our finding of strong C-RAF expression in the endothelial cells around blood vessels (Fig. 7). However, there were also some tumor cells strongly stained (Fig. 7). C-RAF is able to induce transcription of the multidrug resistance gene mdr-1 and its activation has been associated with multidrug resistance of tumor cells (18,74,75). Therefore, C-RAF may exert two essential functions in GBM cells: it could protect tumor cells against chemotherapeutics and it might promote angiogenesis and thereby advance oxygen supply within the tumor.

Oxygen supply is essential for the metabolism of cells. In contrast to normal cells, tumor cells have adapted to hypoxic conditions by switching to anaerobic glycolysis (Warburg effect), which is characterized by high rates of glucose consumption and reduced rates of oxidative phosphorylation, causing high lactate production even in the presence of oxygen (76). Recently, we showed that A-RAF directly binds to the glycolytic enzyme pyruvate kinase M2 (M2-PK) (77), induces transition of the dimeric to the tetrameric active form of M2-PK and thereby favors glycolytic energy production and promotes cell transformation and tumorigenesis (77-79). Glioblastomas are hypoxic tumors (62) and although the role of A-RAF remains poorly defined (62) and although the role of A-RAF remains poorly defined (62), it is the RAF kinase with weakest activity (75), its link to regulation of tumor cell metabolism may be of importance in view of its negative effect on GBM patient's survival.

In conclusion, we showed that RAF proteins may play an important role during development of human malignant gliomas. Although RAF mutations are a rare event in GBM, overexpression on mRNA and protein level was regularly found. RAF expression was correlated with the patient's prognosis. Most probably, B-RAF expression causes cell cycle arrest and senescence of cells (24,54,70-72) and therefore exerts the observed positive effect for the patient's survival. In functional assays, A-RAF and C-RAF expression did not have any influence on proliferation or migration of GBM cells (Fig. 8) (31). Therefore, they might be important for other cellular processes. C-RAF for example positively regulates survival of and tube formation by endothelial cells and may promote angiogenesis (31). A-RAF might be involved in regulation of tumor cell metabolism (77,78) and thereby support proliferation under hypoxic conditions. Therefore, specifically targeting RAF proteins might be a valuable treatment option (6). However, initially specific RAF functions during tumorigenesis of malignant gliomas have to be elucidated.

Acknowledgements

We thank Reinhold Krug (MSZ) for sequencing and Thomas Freiman (Neurochirurgische Klinik, Neurozentrum, University-Hospital Freiburg im Breisgau, Germany) for normal brain control tissue. We are very grateful to Michaela Kapp (University of Würzburg, Department of Gynaecology and Obstetrics, Würzburg, Germany) for technical assistance. This project was supported by Interdisziplinäres Zentrum für Klinische Forschung der Universität Würzburg (C.H. and G.H.V.).

References


21. Hagemann C and Marais R: Mutations of C-RAF are rare in human cancer because C-RAF has a low basal kinase activity with B-RAF. Cancer Res 65: 9719-9726, 2005.


